US Bancorp DE reduced its holdings in Core Laboratories (NYSE:CLB) by 26.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 78,809 shares of the oil and gas company’s stock after selling 28,302 shares during the period. US Bancorp DE’s holdings in Core Laboratories were worth $8,632,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Janus Henderson Group PLC increased its stake in Core Laboratories by 1.3% in the 2nd quarter. Janus Henderson Group PLC now owns 5,002 shares of the oil and gas company’s stock valued at $506,000 after buying an additional 64 shares during the last quarter. Advisory Services Network LLC increased its stake in Core Laboratories by 33.3% in the 2nd quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock valued at $138,000 after buying an additional 341 shares during the last quarter. Kingfisher Capital LLC increased its stake in Core Laboratories by 3.1% in the 2nd quarter. Kingfisher Capital LLC now owns 12,190 shares of the oil and gas company’s stock valued at $1,235,000 after buying an additional 368 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its stake in Core Laboratories by 60.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 1,096 shares of the oil and gas company’s stock valued at $120,000 after buying an additional 414 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Core Laboratories by 63.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock valued at $114,000 after buying an additional 439 shares during the last quarter.

Several brokerages have issued reports on CLB. TheStreet upgraded shares of Core Laboratories from a “c” rating to a “b-” rating in a research note on Thursday, February 1st. Royal Bank of Canada set a $125.00 price target on shares of Core Laboratories and gave the company a “buy” rating in a research note on Tuesday, January 30th. Zacks Investment Research lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a research note on Monday. Scotiabank set a $136.00 price target on shares of Core Laboratories and gave the company a “hold” rating in a research note on Wednesday, October 25th. Finally, ABN Amro upgraded shares of Core Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, October 25th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the stock. Core Laboratories currently has an average rating of “Hold” and an average target price of $111.70.

Core Laboratories (NYSE:CLB) opened at $106.99 on Friday. The firm has a market cap of $4,887.11, a PE ratio of 55.35 and a beta of 1.44. Core Laboratories has a 52 week low of $86.55 and a 52 week high of $121.39. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.66 and a current ratio of 1.98.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, January 31st. The oil and gas company reported $0.58 earnings per share for the quarter, hitting the consensus estimate of $0.58. The company had revenue of $172.00 million for the quarter, compared to analyst estimates of $171.92 million. Core Laboratories had a net margin of 12.60% and a return on equity of 58.25%. Core Laboratories’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.41 EPS. research analysts predict that Core Laboratories will post 2.67 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 16th. Stockholders of record on Friday, January 26th will be paid a dividend of $0.55 per share. The ex-dividend date is Thursday, January 25th. This represents a $2.20 annualized dividend and a dividend yield of 2.06%. Core Laboratories’s dividend payout ratio is presently 117.02%.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/02/09/core-laboratories-clb-shares-sold-by-us-bancorp-de.html.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.